Neurol. praxi. 2017;18(5):322-325 | DOI: 10.36290/neu.2017.105

Efficacy and safety of ocrelizumab in multiple sclerosis

MUDr. Radek Ampapa
Neurologické oddělení Nemocnice Jihlava

Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system. T and B lymphocytes play an important rolein the pathophysiology of the disease. The majority of anti-inflammatory drugs used in the treatment of multiple sclerosis affect theactivation of T lymphocytes in particular. Ocrelizumab is a novel monoclonal antibody that causes selective depletion of CD20 B lymphocytes.The drug has shown its efficacy in treating multiple sclerosis in both relapsing-remitting and progressive forms. In terms ofserious adverse effect rates, no statistically significant differences were found among ocrelizumab, interferon beta-1a, and placebo.

Keywords: multiple sclerosis, ocrelizumab, rituximab, CD20

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ampapa R. Efficacy and safety of ocrelizumab in multiple sclerosis. Neurol. praxi. 2017;18(5):322-325. doi: 10.36290/neu.2017.105.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Calabresi PA. B-Cell depletion - a frontier in monoclonal antibodies for multiple sclerosis. N Engl J Med 2017; 376: 280-282. Go to original source... Go to PubMed...
    2. Frohman EM, Racek MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-55. Go to original source... Go to PubMed...
    3. Hauser SL, Bar Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H and Kappos L, for the OPERA I and OPERA II Clinical investigators. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 2017 Jan 19; 376(3): 221-234. Go to original source... Go to PubMed...
    4. Havrdova E, Galleta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical a radiological disease aktivity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260. Go to original source... Go to PubMed...
    5. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, Serafini B, Aloisi F, Roncaroli F, Magliozzi R, Reynolds R. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011: 2755-2771. Go to original source... Go to PubMed...
    6. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779-1787. Go to original source... Go to PubMed...
    7. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar Or A, Comi G, De Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, for the ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19; 376(3): 209-220. Go to original source... Go to PubMed...
    8. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74: 1860-1897. Go to original source... Go to PubMed...
    9. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
    10. Traboulsee A, Giovannoni G, Bar-Or A, Comi G, Hartung HP, Havrdová E, Kappos L, Lublin F, Selmaj K, Han J, Julian L, Belachew S, Hauser SL. NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III Studies. Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2017; February 23-25; Orlando, FL, USA.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.